|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Shire's success in phase 3 trials of Lanadelumab may mean it has also found a cure for a damaged track record in M&A.
Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD
Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home
Shire plc SHP shares shot to the top of the FTSE 100 Tuesday after the drugmaker beat expectations for earnings in the first-quarter and reiterated its full-year guidance.
Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism
Shire launches campaign to raise global awareness during World PI Week
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...
Benchmarks were higher on Tuesday following strong gains among commodity, consumer and airline stocks
Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients
Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care